<DOC>
	<DOCNO>NCT01689324</DOCNO>
	<brief_summary>This study design assess immunogenicity safety tetanus toxoid , reduce diphtheria toxoid acellular pertussis vaccine ( ADACEL® , Tdap vaccine ) booster dose adolescent Japan . Primary Objective : - To assess immunogenicity Tdap ( SP306 ) administer single dose Japanese adolescent Secondary Objective : - To assess safety Tdap vaccine administer single dose Japanese adolescent .</brief_summary>
	<brief_title>Study Tetanus Toxoid , Reduced Diphtheria Toxoid Acellular Pertussis Vaccine ( ADACEL® ) Booster Adolescents</brief_title>
	<detailed_description>All participant receive single booster dose Tdap vaccine ( ADACEL® ) Day 0 undergo immunogenicity assessment blood sample provide prior , 28 day post-vaccination . Tolerability safety monitor 28 day post-vaccination .</detailed_description>
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Tetany</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Aged 11 12 year day inclusion Informed consent form assent form sign dated parent ( ) / legal representative subject respectively Completed childhood vaccination diphtheria , pertussis tetanus ( i.e , receive 4 dos Japaneseproduced tetanus toxoid , diphtheria toxoid acellular pertussis vaccine absorb [ DTaP vaccine ] ) , confirm check immunization record yet undergone additional adsorbed Diphtheria Tetanus toxoid ( DT ) vaccination Able attend schedule visit comply trial procedure For female subject , either premenarchal , postmenarchal negative urine pregnancy test . Any condition disease , opinion investigator would pose health risk subject might interfere ability participate fully study might interfere evaluation vaccine would otherwise make participation inappropriate accord investigator 's clinical judgment History diphtheria , tetanus , pertussis , confirm either clinically , serologically , microbiologically Known systemic hypersensitivity vaccine component history life threaten reaction vaccine contain substance study vaccine Vaccination last 5 year tetanus , diphtheria , and/or pertussis Known suspect congenital immunodeficiency , current / previous acquire immunodeficiency , current / previous receipt immunosuppressive therapy anticancer chemotherapy radiation therapy , current / previous ( within last 6 month ) systemic corticosteroid therapy Participation another clinical trial investigate vaccine , drug , medical device , medical procedure 4 week precede trial inclusion Planned participation another clinical trial present trial period Receipt blood bloodderived product past 3 month , might interfere assessment immune response Receipt vaccine within 4 week precede trial vaccination , except influenza vaccination , may receive least 2 week study vaccine Planned receipt vaccine trial period Clinical known serological evidence systemic illness include Hepatitis B , Hepatitis C and/or Human Immunodeficiency Virus ( HIV ) infection At high risk diphtheria , tetanus pertussis infection trial Known pregnancy , positive urine pregnancy test Currently breastfeed child Known thrombocytopenia , contraindicate intramuscular ( IM ) vaccination , history thrombocytopenia Bleeding disorder , receipt anticoagulant 3 week precede inclusion , contraindicate IM vaccination History acute disseminate encephalomyelitis , encephalopathy , GuillainBarré Syndrome ( GBS ) , autoimmune disease Deprived freedom administrative court order , emergency setting , hospitalize involuntarily Current alcohol abuse drug addiction might interfere ability comply trial procedure Identified employee Investigator , study center , studyaffiliated vendor , Sponsor , direct indirect involvement propose study study direction Investigator study center ; identify spouse child ( whether natural adopt ) employee .</criteria>
	<gender>All</gender>
	<minimum_age>11 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Pertussis</keyword>
	<keyword>Tetanus</keyword>
	<keyword>Diphtheria</keyword>
	<keyword>Acellular pertussis</keyword>
	<keyword>ADACEL®</keyword>
	<keyword>Tdap vaccine</keyword>
</DOC>